Neutral endopeptidase inhibition: Augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Clinical Science

Volumn 91, Issue 3, 1996, Pages 283-291

  Rademaker, Miriam Tessa ^a   Charles, Christopher John ^a   Espiner, Eric Arnold ^a   Nicholls, Michael Gary ^a   Richards, Arthur Mark ^a   Kosoglou, Teddy ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cyclic GMP; Haemodynamics; Natriuresis; Ventricular pacing

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; RENIN; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIURESIS; ENZYME INHIBITION; FEMALE; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HORMONE BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; SHEEP; VASCULAR RESISTANCE;

EID: 0029815384     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0910283     Document Type: Article

References (34)

1. Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, Rogers WL. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995; 22: 63-9.
2. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
3. Crozier IG, Nicholls MG, Ikram H, Espiner EA, Gomez HJ, Warner NJ. Hemodynamic effects of atrial peptide infusion in heart failure. Lancet 1986; 2: 1242-4.
4. Herrmann HC, Palacios IF, Dec GW, Scheer JM, Fifer MA. Effects of atrial natriuretic factor on coronary hemodynamic and myocardial energetics in patients with heart failure. Am Heart J 1988; 115: 1232-8.
5. Yoshimura M, Yasue H, Morita E, et al, Hemodynamic, renal, and hormonal responses to brain natriuretic peptide in patients with congestive heart failure. Circulation 1991; 84: 1581-8.
6. Norman JA, Little, D Bolger M, di Donate G. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 1991; 175: 22-30.
7. Helin K. Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects. Scand J Clin Invest 1993; 53: 843-51.
8. Kukkonen P, Vuolteenaho O, Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Endocrinology (Baltimore) 1992; 130: 755-65.
9. Fitzpatrick MA, Rademaker MT, Charles CJ, et al. Acute hemodynamic, hormonal and renal effects of neutral endopeptidase inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992; 19: 635-40.
10. Seymour AA, Asaad MM, Lanoce VM, Fennell SA, Cheung HS, Rogers WL. Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc Res 1993; 27: 1015-23.
11. Yasuhara M, Yamaguchi M, Shimizu H, et al. Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure. Pharm Res 1994; 11: 1726-30.
12. Sybertz EJ, Chiu PJS, Watkins RW, Vemulapalli S. Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation. J Hypertens 1990; 8 (Suppl. 7): S161-7.
13. Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992; 82: 619-23.
14. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep Am J Physiol (In press).
15. Fitzpatrick MA, Nicholls MG, Espiner EA, et al. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol 1989; 256: H1052-9.
16. Fitzpatrick MA, Rademaker MT, Frampton CM, et al. Hemodynamic and hormonal effects of renin inhibition in ovine heart failure. Am J Physiol 1990; 258: H1625-31.
17. Charles CJ, Espiner EA, Cameron VA, Richards AM. Hemodynamic, renal, and endocrine actions of ANF in sheep: effect of 24-h, low-dose infusions. Am J Physiol 1990; 258: R1279-85.
18. Yandle TG, Aitken GD, Fisher SF, Rademaker MT, Espiner EA, Nicholls MG. Ovine brain natriuretic peptide: identity measurement and regulation [Abstract]. J Hypertens 1994; 12: 50S.
19. Aitken GD, George P,Espiner EA, Characterisation of ovine natriuretic peptide genomic DNA sequences [Abstract]. J Hypertens 1994; 12 (Suppl. 3): 174.
20. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG, Dargie HJ, Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens 1990; 3: 682-7.
21. Hashimoto Y, Nakao K, Hama N, et al. Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res 1994; 11: 60-4.
22. Hirata Y, Suzuki E, Hayakawa H, et al. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol 1994; 23: 283-90.
23. Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993; 22: 231-6.
24. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291: 83-8.
25. Charles CJ, Espiner EA, Richards AM, Nicholls MG, Yandle TG. Comparative bioactivity of atrial, brain and C-type natriuretic peptides in conscious sheep. Am J Physiol (In press).
26. Bellemann P, Nauser D. Modulation of ANP receptor-mediated cGMP accumulation by atrial natriuretic peptides and vasopressin in A10 vascular smooth muscle cells. J Recept Res 1988; 8: 407-10.
27. Rankin AJ, McWilliam TM, Swipt FV, Triggle CR. Studies of the desensitization of atrial natriuretic factor and nitroglycerin in rat aortic rings. Gen Pharmacol 1990; 21: 887-91.
28. Hirata Y, Tomita M, Takata S, Yoshimi H. Vascular receptor binding activities and cyclic GMP responses by synthetic human and rat atrial natriuretic peptides (ANP) and receptor down-regulition by ANP. Biochim Biophys Res Commun 1985; 128: 538-46.
29. Munzel T, Drexler H, Holtz J, Kurtz S, Just H. Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation 1991; 83: 191-201.
30. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362-74.
31. Cavero PG, Marguliea KB, Winaver J, Seymour AA, Delaney NG, Burnett JC. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990; 81: 196-201.
32. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993; 266: 872-83.
33. Shima M, Seino Y, Torikai S, Imai M. Intrarenal localization of degradation of atrial natriuretic peptide in glomeruli and cortical nephron segments. Life Sci 1988; 43: 357-63.
34. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3: 145-51.